8e sommet annuel sur les thérapies CAR et TCR
Cell and gene therapy (CGT) manufacturing offers immense potential for treating diseases; however, the process is long, expensive and comes with a high risk of failure. For biotech companies with limited resources, conducting CGT trials can be a challenging endeavor but, it is possible to set up and execute a successful trial even with constrained resources. Syneos Health aims to answer the following questions:
- With limited resources, how can small biotech set up a CGT therapy trial effectively?
- What challenges have we encountered, and what are the main lessons learned?
- How do we find the right clinical research partner to work with?
Meet with us at the 8th Annual CAR-TCR Summit (BOOTH #F66) to discuss how our collective knowledge and insights can be fully leveraged to deliver solutions specific to the needs of your trial—and make each study as safe and effective as possible for patients.
Panel Discussion
Building New Clinical Programs & Operations in Small Biopharma | Wednesday, August 30, 11:30 A.M. ET
Additional Resources
Vous voulez en savoir plus? Explore Insights Hub for our latest perspectives, subscribe to our podcast, or click the resources below:
Capabilities
- Cell and Gene Therapy Development Engine at Syneos Health
- Cell and Gene Market Access Solutions
- Streamlining the Development of Cell and Gene Therapies for Patients in Need
- Cell & Gene Market Access Solutions to Get Life-saving Therapies to Patients
- Synteract: Our History and Our Promise
Connaissances
- Strategies for Small Biotech in the Development of Cell Therapy Trials
- L’importance d’une bonne stratégie de mise sur le marché pour la commercialisation des thérapies cellulaires
- Designing Protocols Based on Patient Burden Scores: Trial Design Application Guides Study Design for Gene Therapies
- WEBINAIRE | L’importance d’une stratégie intégrée et précoce en matière de preuves pour les thérapies cellulaires et géniques
Learn more about our Cell & Gene Therapy expertise.
